Anthony Sergnese

FIREFLI capsule close-up

FIREFLI

Lab for Translational Engineering, 2024–2025

FIREFLI is an ingestible, pill-sized device designed to activate in the small intestine and diagnose mesenteric ischemia. During development, the system faced two critical engineering challenges: existing circuit boards communicated unreliably via I²C, and no mechanism existed to ensure the device powered on only in the small intestine. Addressing these issues was essential for conserving battery life over the full intestinal transit time and for ensuring diagnostic accuracy.


I first debugged the electronics system, identifying a logic-level mismatch (2.1 V output vs. 1.8 V required) as the root cause of failed communication. I designed an intermediate level-shifting PCB using Altium Designer to slot between the existing circuit boards, which restored full system function. In parallel, I developed a passive, pH-activated trigger by coating copper electrodes with Eudragit L100-55, a polymer that dissolves only in neutral intestinal fluid. This mechanism prevented premature capsule activation in the stomach while reliably powering the device in the small intestine. With these solutions, I assembled four test devices that completed nine successful in vivo trials. Using pilot trial data, I also wrote algorithms to average healthy versus ischemic signals and set diagnostic thresholds, achieving 90% diagnostic accuracy with 98% sensitivity and 85% specificity. In addition to the engineering and experimental work, I constructed the methods section of a manuscript describing FIREFLI’s design, validation, and in vivo testing.